Teva Shares Rally, Forecast 'Very Strong Launch' for Long-awaited Ajovy Migraine Treatment
The company added that it expected to launch its generic version of the best-selling EpiPen allergy treatment in the current quarter
Teva Pharmaceutical
Business in Brief: Teva Leads Sharp Rise in Tel Aviv Shares
Little-known Krausz Metal Industries fetches $135 million from U.S. buyer ■ Boards approve merger of JOEL into parent company Equital ■ Israel Chemicals profit rose 16.5% in quarter
Teva Raises 2018 Earnings Outlook, Says 'Very Good Signs' of New Drug Launch
Teva has been counting on its long-awaited migraine drug to revive its fortunes after suffering a drop in revenue
Teva Loses Negotiations Over New Migraine Drug, Stock Falls 5 Percent
The Israeli pharmaceutical company's new drug will not be covered by U.S. prescription benefits manager, though it's competitors will.
Lilly Defeats Teva Patent Lawsuits Over Migraine Drug
Teva was trying to block its competitor from bringing its migraine drug Emgality to market in the United States
Business in Brief: Foamix Soars on Trials for Acne Treatment
Opko chief, ex-Teva chairman Phillip Frost charged with share manipulation in U.S. ■ Generation Capital takes 50% stake in power plant operator Rapac Energy ■ TASE ends lower after long holiday weekend
Business in Brief: Israeli Government Gained $275 Million by Delaying Leumi Share Sale
Teva offers to buy back $400 million in bonds ■ RADA cashes in on drone-threat fears ■ TASE closes in the red, dragged down by Wall Street
FDA Approves Teva's Generic Version of Mylan's EpiPen
Teva Pharmaceutical's version of Mylan NV's EpiPen to provide 'lower-cost option' for patients 'living with severe allergies,' FDA commissioner says
Warren Buffett Buys $60 Million Worth of Teva in the Dip
Berkshire Hathaway also massively invested more in Goldman Sachs and Apple
Teva Shares Tumble After Company Disappoints Markets
The pharmaceutical company is in a $28.4 billion debt. Analysts says the company still lacks growth drivers